NCT07381933 The Effect of Consumed Berries on Extracellular Vesicle Signalling in the Body
| NCT ID | NCT07381933 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oulu |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-23 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-23 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines how berry consumption influences the signaling and distribution of extracellular vesicles (EVs) in the human body. EVs are small bilipid-layered nanoparticles released by cells. EVs carry proteins, lipids, and genetic material, and play a key role in cell-to-cell communication. The composition of EVs reflects the state of their cells of origin, and EVs can affect other cells by delivering their biological contents. EVs offer significant potential for both diagnostics and new therapies. Recent research has shown that EVs can be found in blood, urine, sweat, and can even cross biological barriers such as the blood-brain barrier and placenta. Many living organisms, including mammalian cells, bacteria, and plants, release EVs. Berries such as cloudberries and lingonberries have demonstrated positive effects on gut microbiota and metabolism, supporting digestive and metabolic health. In this study, a nutritional intervention will be conducted to investigate the effects of berry consumption on extracellular vesicle signaling of human cells and the gut microbiota, as well as the biodistribution of berry-derived vesicles in the human body.
Eligibility Criteria
Inclusion Criteria: * Age 18-50 * Individuals of all heights and weights and both female and male sexes are accepted * Written informed consent is required from all study participants * Use of probiotics is allowed, but the usage will be reported Exclusion Criteria: * Known or suspected allergy to cloudberries or lingonberries * Current dermatological or gastrointestinal conditions requiring treatment or interfering the sampling * Renal failure * Type 1 or type 2 diabetes * Pregnancy * Immunodeficiency or any condition affecting the immune system, e.g. chronic viral infection * Ongoing antibiotic treatment or antibiotic treatment within the past 3 months * Immunosuppressive medication or other medication that can be influenced by the intervention
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07381933 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07381933 currently recruiting?
Yes, NCT07381933 is actively recruiting participants. Contact the research team at nea.hakkarainen@student.oulu.fi for enrollment information.
Where is the NCT07381933 trial being conducted?
This trial is being conducted at Oulu, Finland.
Who is sponsoring the NCT07381933 clinical trial?
NCT07381933 is sponsored by University of Oulu. The trial plans to enroll 60 participants.